PRED G SUMMARY
(gentamicin and prednisolone acetate
ophthalmic suspension, USP) 0.3%/1.0%
PRED-G® sterile ophthalmic suspension is a topical anti-inflammatory/anti-infective combination product for ophthalmic use.
PRED-G® suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.
Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns or penetration of foreign bodies.
The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye.
The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Serratia marcescens.
Published Studies Related to Pred G (Gentamicin / Prednisolone Ophthalmic)
Side effects of postoperative administration of methylprednisolone and gentamicin into the posterior sub-Tenon's space. [2007.05]
PURPOSE: To assess the incidence of postoperative emetic side effects after the administration of methylprednisolone and gentamicin into the posterior sub-Tenon's space at the end of routine cataract surgery. SETTING: St. Luke's Hospital, Gwardamangia, Malta... CONCLUSIONS: The administration of methylprednisolone and gentamicin in the posterior sub-Tenon's space was related to a high incidence of side effects including nausea, vomiting, and headache. All adverse effects were self-limiting.
Clinical Trials Related to Pred G (Gentamicin / Prednisolone Ophthalmic)
Prednisone Timed-Release Tablet (TRT) Study: TRT Formulation of Prednisone Compared to Standard Prednisone in Patients With Rheumatoid Arthritis [Completed]
The objective of this study is to investigate if low doses of prednisone TRT, given at night
and, with active drug release at 2 am, are more effective in controlling joint stiffness, and
other disease symptoms of rheumatoid arthritis than standard prednisone given in the morning.
Treatment duration per patient takes 12 months (the double-blind comparative study takes 3
months; 9 months subsequent open treatment on the TRT-medication).
Prednisone-Placebo vs Prednisone-Valacyclovir in Bell´s Palsy [Completed]
Since steroids carry a moderate beneficial effect in Bell's palsy, and to address this
question, valacyclovir was added to prednisone for the treatment of this condition.
Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone [Recruiting]
This protocol is a single-arm, three-cohort, phase II multicenter study designed to assess
the safety and the efficacy of three all-oral combinations: Velcade with continuous low-dose
melphalan and prednisone (VMP) or with continuous low-dose cyclophosphamide and prednisone
(VCP) or Velcade with low-dose prednisone could be effective and well tolerated (VP).
Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients [Recruiting]
This is a multicenter, randomized, controlled, 3 arm parallel group study designed to
evaluate the efficacy and safety of three all-oral combinations: lenalidomide with
dexamethasone (Rd) in comparison with lenalidomide in association with MP (MPR) and
lenalidomide in association with cyclophosphamide - prednisone (CPR) in newly diagnosed
symptomatic MM patients. This protocol also provides a substudy designed to observe
asymptomatic patients excluded to the protocol that in any case could be inserted in the
Study Comparing Two Tapering Strategies of Prednisone in Myasthenia Gravis [Recruiting]
Pathology - Generalized myasthenia gravis (MG) is cause of muscle weakness that can have a
significant impact on daily life activity but can also be, when respiratory or bulbar
muscles are involved, life-threatening.
Rationale - Additionally to thymectomy, which indication of is still debated in absence of
thymoma, the long-term treatment of generalized myasthenia gravis includes usually
prednisone and azathioprine. However, the most used scheme for prescribing and tapering
corticosteroid in MG resulted in a very important cumulative dose of prednisone. Indeed, at
twelve month, more than 50 percent of patients are still daily treated with at least 18 mg
of prednisone and the proportion of patients who are in remission and no longer taking
prednisone is very low (Palace and NEWSOM Davis, Neurology 1998). Prolonged corticosteroid
therapy is accompanied with various and major side effects, hypertension, osteoporosis,
weight gain, glaucoma. Therefore, tapering, eventually discontinuing, prednisone earlier is
a relevant therapeutic goal.
For this reason, the investigators will compare to the standard one, a strategy consisting
of a rapid decrease in corticosteroid.
Objective - To assess whether, in patients with generalized MG requiring a long-term
treatment with corticosteroids and azathioprine, that the strategy of rapid tapering allows
discontinuing more rapidly the prednisone for equivalent efficacy than the classical
Page last updated: 2007-08-04